이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

표적 항암제에 대한 환자 접근성을 촉진하기 위한 핀란드 국가 연구 (FINPROVE)

2026년 11월 9일 업데이트: Katriina Jalkanen, Helsinki University Central Hospital

알려진 분자 프로파일을 가진 진행성 암 치료의 효능을 결정하기 위해 표적 항암제에 대한 환자 접근을 촉진하기 위한 핀란드 국립 연구

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

연구 개요

상세 설명

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

연구 유형

중재적

등록 (추정된)

250

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Kuopio, 핀란드
        • 모병
        • Kuopio University Hospital
        • 연락하다:
          • Okko Kääriäinen, MD
      • Oulu, 핀란드
        • 모병
        • Oulu University Hospital OYS Cancer Center
        • 연락하다:
          • Sanna Iivanainen, MD. PhD.
      • Tampere, 핀란드
        • 모병
        • Tampere University Hospital Department of Oncology
        • 연락하다:
          • Minna Tanner, MD, PhD
    • Southwest Finland
      • Turku, Southwest Finland, 핀란드
        • 모병
        • Turku University Hospital Cancer Centre
        • 연락하다:
          • Erika Alanne, MD, PhD
    • Uusimaa
      • Helsinki, Uusimaa, 핀란드, 00029
        • 모병
        • Helsinki University Hospital Comprehensive Cancer Center
        • 연락하다:
          • Tanja Juslin
        • 수석 연구원:
          • Katriina Jalkanen, MD, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

  2. ECOG performance status 0-2

  3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

    1. Absolute neutrophil count ≥ 1.5 x 109/l
    2. Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
    3. Platelets > 75 x 109/l (not applicable for hematological patients)
    4. Total bilirubin < 1.5 x ULN
    5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
  4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

  5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

  6. Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

  7. A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

  8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

  9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

  1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

  2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

    1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
    2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
  3. Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention

  4. Patient is pregnant or nursing.

  5. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.

  6. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  7. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  8. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

  9. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

  10. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Alectinib

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

ALK

다른 이름들:
  • 알레센사
실험적: Cobimetinib

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

MEK1, MEK2

다른 이름들:
  • 코텔릭
실험적: Vismodegib

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

Hedgehog

다른 이름들:
  • 에리엣지
실험적: Trastuzumab+Pertuzumab

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

HER2

다른 이름들:
  • 페스고
실험적: Entrectinib

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

NTRK/ ROS1, ALK

다른 이름들:
  • 로즐리트렉
실험적: Atezolizumab

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

PD-L1

다른 이름들:
  • 티센트릭
실험적: Vemurafenib

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

BRAF V600

다른 이름들:
  • 젤보라프
실험적: Regorafenib

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

KIT/BRAF, RET

다른 이름들:
  • 스티바르가
실험적: Apalutamide

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

AR

다른 이름들:
  • 얼리다
실험적: Abemaciclib

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

CDK4/6

다른 이름들:
  • 베르제니오
실험적: Tepotinib

For patients with a molecular tumor profile that can potentially be targeted by tepotinib.

MET ex14

다른 이름들:
  • 테프멧코
실험적: Dabrafenib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

RAF

다른 이름들:
  • 타핀라르
실험적: Trametinib

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

MEK1, MEK2

다른 이름들:
  • 메키니스트
실험적: Dabrafenib+Trametinib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

RAF, MEK1, MEK2

다른 이름들:
  • 타핀란+메키니스트
실험적: Pemigatinib

For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.

FGFR2

다른 이름들:
  • 페마지레

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Disease control rate
기간: 16 weeks

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

16 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of treatment
기간: 5 years

Time on drug

5 years
Adverse Events
기간: 5 years

Treatment-related grade ≥3 and serious adverse events

5 years
Overall response
기간: 5 years

Best overall response (defined as patients by CR, PR, SD)

5 years
PFS
기간: 5 years

Progression free survival

5 years
OS
기간: 5 years

Overall survival

5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 12월 10일

기본 완료 (추정된)

2031년 11월 25일

연구 완료 (추정된)

2032년 11월 25일

연구 등록 날짜

최초 제출

2021년 12월 3일

QC 기준을 충족하는 최초 제출

2021년 12월 3일

처음 게시됨 (실제)

2021년 12월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Investigators plan to share the clinical study report.

IPD 공유 기간

2026-2027

IPD 공유 액세스 기준

Will be made available through European regulatory CTIS programme.

IPD 공유 지원 정보 유형

  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다